• BeOne Medicines’ third-quarter 2026 GAAP net income more than tripled year over year to $384.71 million.
• Revenue climbed 34% to $1.89 billion, while BRUKINSA revenue increased 34% to $1.4 billion from a year earlier.
• Tacabrutideg’s pivotal Phase 2 trial met its primary endpoint of overall response rate in relapsed/refractory chronic lymphocytic leukemia.
• Raised FY26 revenue guidance to $6.9 billion-$7 billion and GAAP operating income outlook to $1.2 billion-$1.3 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief via Business Wire (Ref. ID: 202611050600BIZWIRE_USPR_____20261105_BW790053) on November 05, 2026, and is solely responsible for the information contained therein.